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Abstract. We evaluated the feasibility of using a blockchain technology to create 
a traceability solution for pharmaceutical drugs that would promote compliance 
with recent legislation. Counterfeit and other illegitimate pharmaceutical drugs 
threaten patient safety, drug efficacy, and patient trust. The purpose of the Drug 
Supply Chain Security Act (DSCSA) is to greatly reduce distribution of 
illegitimate drugs by requiring all pharmaceuticals to be serialized and traceable 
from the manufacturer through the supply chain to the dispenser. A software 
application to serialize and track pharmaceuticals must overcome numerous 
obstacles. In particular, the solution must provide a high degree of trust while 
also protecting privacy for manufacturers, distributors, and patients. This 
research will propose that a blockchain-enabled application will solve for many 
of the most challenging needs for this solution. 
1   Introduction 
The Drug Quality and Security Act (DQSA); enacted November 2013; set requirements 
for the compounding safety and security of pharmaceutical products. The law has two 
focus areas. Title I is “The Compounding Quality Act”, which set standards for safety 
and security for compounded drugs. Title II of DQSA is the “Drug Supply Chain 
Security Act” (DSCSA). The DSCSA is further divided into two focus areas. One effort 
establishes license and registration requirements for all wholesale distributors and 
third-party logistics (3PL) providers to ensure proper identification of all legitimate 
members of the supply chain. The second effort requires the consistent traceability of 
pharmaceutical products from the manufacturer to the dispenser within the United 
States. Participants in the supply chain are expected to verify the chain of ownership, 
detect suspicious activity, and respond accordingly as outlined by the law. In addition, 
participants must be able to quickly respond to requests for information from 
enforcement officials. The final outcome of Title II will be the creation of an electronic, 
interoperable traceability system for pharmaceutical products at the package-level by 
2023 [1]. The goal is to use real-time data capture to detect, respond to, and report 
potentially illegitimate drugs faster and more effectively before they can become a 
safety hazard to patients.1 
                                                          
1 AmerisourceBergen. (2017). Serializing Your Products [White Paper]. 
https://www.icsconnect.com/insights/serializing-your-products. 
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The DSCSA was created to curb the circulation and sale of illegitimate 
pharmaceutical products. Illegitimate drug products jeopardize consumer safety and 
cost the pharmaceutical industry almost $40 billion annually [2]. By serializing the 
products and providing traceability from manufacturer to dispenser, participants in the 
supply chain can be protected and have greater assurance of encountering only 
legitimate pharmaceutical products. However, achieving this goal requires creating a 
reliable system of record with appropriate visibility to identify legitimate 
pharmaceuticals for all participants in the supply chain. Since members in the supply 
chain have compelling business reasons not to share information on inventory, a key 
challenge to ensuring compliance with traceability requirements will be establishing 
trust among stakeholders. 
Blockchain distributed ledger technology is causing controversy in the industry, with 
some touting its capability to revolutionize computing while others are not convinced. 
Gartner lists blockchain as on ‘the peak of inflated expectations’.2 In an attempt to 
clarify the real opportunity for blockchain, SAP surveyed “hundreds of organizations 
currently engaged in blockchain-related activities”. Of the people surveyed, 92% 
believe blockchain represented a new opportunity in the marketplace and of those 63% 
sited supply chain applications as the most promising use cases for the technology.3 
Blockchain applications are appropriate when trying to introduce trust into a trust-less 
system. As such, providing traceability of pharmaceuticals through the supply chain is 
a suitable use case for a blockchain implementation. This review demonstrates how a 
blockchain technology can provide functionality that benefits supply chain in general, 
and traceability of pharmaceuticals in particular.  
The case for the feasibility of blockchain for pharmaceutical supply chain is built by 
first delving into the pharmaceutical supply chain and the DSCSA in sections 2 and 3 
respectively. Then we present the characteristics of a blockchain distributed ledger in 
the context of supply chain applications in section 4. In section 5, we explore how 
blockchain is currently being implemented in supply chain applications. . The paper 
concludes with ethical considerations presented in section 6, conclusions in section 7 
and a summary in section 8. As this project was originally initiated as a Proof of 
Concept, efforts to build the POC are outlined in the Appendix. 
2   Pharmaceutical Supply Chain 
The pharmaceutical supply chain is comprised of excipient manufactures, the 
manufacturer of the drug, repackagers, wholesalers, logistics partners, and ultimately 
the dispenser. The FDA provides a simplified illustration of the pharmaceutical supply 
chain presented below.4 
                                                          
2  Gartner. https://blogs.gartner.com/smarterwithgartner/files/2017/08/Emerging-Technology-
Hype-Cycle-for-2017_Infographic_R6A.jpg 
3 SAP. https://news.sap.com/blockchain-a-study-rooted-in-reality/ 









Fig 1. FDA: Simplified View of the Pharmaceutical Supply Chain 
 
Despite the simplified diagram, the pharmaceutical supply chain spans many 
geographical regions and involves numerous parties. The pharmaceutical supply chain 
contains excipient manufacturers. Excipients are substances other than the 
pharmacologically active drug which are included in the manufacturing process or are 
contained in a finished pharmaceutical product5. Only 6 percent of pharma sales are 
direct from the manufacturer. Various regulations for things such as 
Medicare/Medicaid compensation and transparency regarding cost revelation from 
drug wholesalers and manufacturers continually impact the decision-making of pharma 
supply chain managers and most product flow through a complex web of 
manufacturers, repackagers, and wholesalers.[3] Repackagers are companies that buy 
drugs from a manufacturer or a wholesale distributor and then put the drug into a new 
package type, such as putting the drug into a smaller quantity package or moving units 
from bottles into a blister card. Transfer of the drug from the manufacturer can be to a 
repackager, a wholesaler, or directly to a dispenser; such as a hospital, non-specialty 
pharmacy distributor, or specialty pharmacy. A wholesaler may warehouse the product 
before selling and transporting to another wholesaler or a dispenser. The end of the 
pharmaceutical supply chain is the dispensing of the drug to a patient. 
The complex nature of the pharmaceutical supply chain includes the fee-for-service 
model between the wholesaler and manufacturer. Contracts between drug 
manufacturers and wholesalers help ensure that wholesalers maintain a supply agreed 
upon by the manufacturer and wholesaler in exchange for a fee paid to the wholesaler 
by the manufacturer. This arrangement helps the manufacturer to adequately procure 
raw materials for their drug and to manufacture their drug in accordance with likely 
demand. Without this contract in place, wholesalers may buy in excess to hedge against 
price increases which would artificially inflate demand [4].  
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GlobalData predicts that the estimated value of the US Pharmaceutical market will 
increase from just under $400 billion in 2014 to almost $550 Billion by 2020 [5]. The 
complexity of the supply chain increases as new drugs and new types of drugs are 
developed, more functions are outsourced globally, modern technology is introduced, 
and new regulations are enacted. Considering the increasing complexity of the supply 
chain and the enormous monetary value at stake, it’s not surprising that securing the 
pharmaceutical supply chain both urgent and challenging.  
2.1   Risks in Pharmaceutical Supply Chain 
The top three risks to the supply chain are 1) theft or diversion, 2) introduction of 
counterfeit medicines, and 3) contamination of medicines during manufacturing, 
storage, or distribution [5]. A diverted product has been removed from the normal 
United States supply chain and then reintroduced for sale. This may include a drug 
labeled for sale outside the US but then introduced into the US market, or a drug 
transported outside of the US but then reintroduced within the US supply chain [6]. 
Provenance and authenticity are hard to verify for diverted drugs, raising questions 
about safety and effectiveness. According to the FDA, a counterfeit drug is one in which 
the container or labeling falsely represents a stakeholder in the supply chain, such as 
the manufacturer, processor, packer, or distributor of the drug. A counterfeit drug is 
sold with the intent to defraud and represents numerous risks to the consumer. 
Examples include products that contain none of the active ingredient, an inappropriate 
dosage of the active ingredient, or ingredients not on the label. The product may have 
ingredients not in the original, meaning the specific combination has not been tested or 
approved by the FDA. In 2008, a counterfeit version of the blood thinner heparin may 
have contributed to the deaths of 81 people in the United States [5].  
Typically, the objective of a supply chain is to maximize overall value created. 
Supply chain management often focuses on cost reductions and efficiencies to achieve 
that goal [7]. Considering the many avenues for fraud with potentially significant 
adverse consequences for the patient, pharmaceutical supply chain management must 
prioritize safety for the end user. Often, added safety measures and cost controls are 
opposing goals. The DSCSA is first seeking to assure the safety of the pharmaceutical 
supply chain by decreasing and detecting incidents representing the top risks of theft, 
diversion and counterfeiting, but in doing so may also protect supply chain participants 
from significant financial loss as well.  
2.2   Lack of Integration across Pharmaceutical Supply Chain 
As complex as the physical supply chain is, the information flow, document exchange, 
and payment processes are even more complex. Think of each organization in the chain 
as having its own inventory/receiving/payables/accounting systems behind their 
firewall. These systems represent a myriad of different platforms, protocols, database, 
and data models, each operating independently within each participant with no inherent 
trust across the supply chain. In fact, within one supplier, systems may be operating 
with limited integration. Even as operations move to the cloud, the systems are still 
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independently owned and operated, with each entity owning their data if not the 
applications and infrastructure. Connecting this collaboration of buyers and sellers is 
an array of third-party data transfer services that ‘map’ the buyer’s data to the seller’s 
data to facilitate electronic transfers of orders and other information. Electronic Data 
Interchange (EDI), Hub models and cloud integration solutions provide some 
connectivity, but there is no common data model used end-to-end across the supply 
chain [8]. Plus, even with electronic transfer and data interchange, some level of manual 
intervention frequently remains. For example, a person may need to enter the order, and 
someone on the dock has to receive the shipment and verify the count and contents. 
These activities may require manual data entry that introduces an opportunity for 
human error.  
Along with other perishable products, pharmaceutical products are increasingly 
monitored for temperature and other environmental conditions during shipping and 
storage. Drugs can be rendered ineffective if exposed to adverse environmental 
conditions. Leveraging RFID technology and the connectedness of the Internet of 
Things (IoT), more companies are piloting programs to embed sensors within product 
shipments then monitor and analyze the resulting data to be sure the quality of the 
product was not compromised as well as to be able to track and locate containers in a 
shipment [9]. While obviously providing value and increasing safety, this also creates 
more complexity as that data must be received, analyzed, and used as part of the 
contractual agreement. 
Furthermore, each participant may have a financial partner, such as a bank, 
performing trade finance functions on their behalf. For example, the seller’s bank will 
guarantee that the seller can supply the product and has delivered what was agreed. The 
buyer’s bank guarantees that the buyer has received what was delivered and is able to 
pay. Banks may provide letters of credit, document collection, buyer/seller credit, bank 
guarantees, trades insurance, and other trade finance services to participants in the 
supply chain. The need for trusted intermediaries effectively doubles the participants in 
the transaction and drives complexity [8].  
Theoretically, if the parties were sharing a blockchain, these trade services could be 
eliminated, but that is outside the scope of what is required by the DSCSA, but the 
requirement to provide traceability of drugs is a core requirement within the 
information flow of the pharmaceutical supply chain. If there were an end-to-end data 
exchange standard already defined for the pharmaceutical supply chain, then perhaps 
implementing DSCSA would not be as large a challenge.  
3   Drug Supply Chain Security Act (DSCSA) 
The DSCSA stipulates the drugs and drug transactions that are covered by the act. The 
DSCSA applies to all prescription drugs in “finished dosage form for administration to 
a patient without further manufacturing” [1]. Excipient manufactures are excluded from 
provisions. The DSCSA does not apply to blood or blood components intended for 
transfusion, radioactive drugs or biologics, imaging drugs, certain IV products, medical 
gas, homeopathic drugs, and lawfully compounded drugs. The DSCSA applies to all 
transactions where a change of ownership occurs unless specifically exempted. 
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Exemptions include intracompany distributions, distributions among hospitals under 
common control, public health emergencies, dispensing pursuant to a prescription, and 
transfer of approved animal drugs [1].  
The primary activity being regulated is the transfer of ownership of the 
pharmaceutical. With each change in ownership, “product tracing information” should 
be exchanged and consists of three types of information:   
Transaction Information (TI). The TI includes name of the product, the strength 
and dosage form, the National Drug Code (NDC) number, the container size for 
individual saleable units, the lot number, the date of the transaction, the date of 
shipment, and the business name and address from whom and to whom ownership is 
being transferred.[1] The NDC is a three-segment number comprised of the labeler 
code, the product code, and the package code. The FDA publishes the NDC numbers 
for finished drugs in the NDC Directory, which is updated daily. Future requirements 
may also include the number of containers, meaning the number of individually 
saleable units within the lot [10].  
Transaction History (TH). The TH details the transaction information above for 
each prior transaction going back to the manufacturer of the product. This information 
establishes the chain of ownership that validates the pharmaceutical is legitimate.[1] 
Transaction Statement (TS). The TS establishes accountability under the law for 
the entity transferring ownership. The entity transferring ownership attests that they: 
are properly authorized under DSCSA, received the product from an entity authorized 
under DSCSA, received TI and TS from the prior owner as required under the law, did 
not knowingly ship a suspect product, have systems and processes in place to comply 
with verification requirements, did not knowingly provide false transaction 
information, and did not knowingly alter the transaction history [1].  
Any entity who takes ownership of a covered drug from the manufacture of the final 
form through the dispenser is impacted by the act. Repackagers have most of the same 
requirements that manufacturers do, plus they have many of the wholesale distributor 
requirements. Under DSCSA, entities that own the drug may also be “repackagers”, 
such as a hospital that repackages bulk medication into individual units used with 
automatic dispensers. 
3.1   Validation Requirements 
A drug is considered a suspect product if there is reason to believe it was potentially 
counterfeited, diverted, stolen, part of a fraudulent transaction, intentionally adulterated 
or is otherwise unfit to distribute for patient safety reasons. An illegitimate product is 
any drug with credible evidence that the product is any of the above.[6] Note that the 
designation does not require proof. With this act, the FDA effectively shifts 
responsibility onto the seller via the TS not just to verify legitimacy of the product, but 
to report and investigate suspected violations. Verification requires establishing 
systems and processes to comply with verification requirements, including the ability 
to: respond to verification requests from the FDA about suspect products, quarantine 
and investigate suspect product, notify trading partners and the FDA of illegitimate 
product within 24 hours of determination, respond to notification of illegitimate 
product, and maintain records.[1] Drug dispensers must be able to comply with requests 
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for information, providing TI, TH, and TS, within two business days while other 
stakeholders in the supply chain must respond one business day [1].  
3.2   Timeline Requirements 
The first milestone of the act allowed the product traceability information to be 
provided in either paper or electronic form. Future milestones include dates when the 
stakeholders in the supply chain must convert from paper to electronic forms. Other 
key dates for the act include when stakeholders must only buy and sell products 
encoded with product identifiers (aka serialized products) as well as when verification 
must switch from lot-level to package-level identifiers.  
 
Fig. 3. Current Timeline of DSCSA 
While some tenants of the act have already been postponed or relaxed, manufacturers 
are under pressure to create systems and processes for traceability to be compliant with 
the law. However, achieving this goal requires creating a reliable system of record with 
appropriate visibility for manufacturers, repackagers, wholesale distributors, and 
dispensers. 
4   What is Blockchain?  
Blockchain is a distributed ledger software technology, meaning it’s a peer-to-peer 
(P2P) public ledger maintained over a network of computers.6 Blockchain provides a 
method for storing information in a distributed fashion without relying on a centralized 
database maintained by a trusted party. The name reveals its method. Transactions are 
clustered into blocks of data that are fit together chronologically into a chain using a 
hashing algorithm that theoretically makes the confirmed records immutable. The 
blockchain is replicated to each participating node on the network and administration 
of the blockchain software is orchestrated by consensus of the participating nodes. 
The term “blockchain” appears to have originated from a reference to a “chain of 
blocks” by Satoshi Nakamoto (pseudonym) in 2008 as a method of validating 
                                                          
6 Scott, Post, Quick “The Best Thing since the Internet: Blockchain” SMU MSDS term paper. 
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ownership of virtual currency in a publicly distributed ledger. Nakamoto’s purpose for 
suggesting a peer-to-peer electronic cash system was to make powerful, centralized 
third parties obsolete by disintermediating financial transactions.[11] In 2009, the first 
application of blockchain technology appeared in the source code for the digital 
cryptocurrency Bitcoin. The Bitcoin blockchain is a public ledger of all the Bitcoin 
transactions that have ever taken place.  
Exposing a transaction’s footprint to the marketplace is called ‘leakage’ and leads to 
a host of undesired market behaviors. Preventing leakage is one reason why transaction 
data is protected in corporate databases. If the blockchain data is public, then what 
prevents competitors from clearly seeing all the transactions? How can a technology 
bind the identity for shared data yet provide anonymity at the same time? Blockchain 
uses encoding technologies to provide privacy, including hashing algorithms and public 
key cryptography.  
The heart of a blockchain is a hashing algorithm7. A hashing algorithm is used to 
map data of varying lengths to an output of fixed length. The values returned by a hash 
algorithm are called “hash values”, “hash codes”, “digests”, or simply “hashes”. Any 
change to the original data would result in a different hash output. Changing a space or 
a letter or even changing a lowercase letter to an uppercase letter in the data would 
cause the output hash value to be different. Since the input hashes to a unique value, 
and it’s infeasible to produce a different block that hashes to the same value, the digest 
provides assurance that the original data has not been altered. The Bitcoin Blockchain 
relies on SHA-256 to create a 256-byte block that represents the input data. These are 
the ‘blocks’ in a blockchain.  
In addition to using hashed encoding, blockchain also uses private key cryptography. 
Public key cryptography is an encryption system that uses pairs of keys to encrypt and 
decrypt data. On the blockchain, each entity is assigned a “public key” available to all 
participants and a “private key” that is provided only to the entity it identifies. The keys 
are used for authentication. A message or document can be encrypted with a private 
key. If the message is legible when it is decrypted using the corresponding public key, 
it’s guaranteed that the holder of the private key is the party that encrypted the message. 
This digital signature serves as an encrypted, unique identifier associated with a 
registered member of the blockchain. Blockchain also supports a concept called M-of-
N signatures or “multisig,” meaning that there exists a total of N cryptographic keys, 
and at least M of them have to be present to decrypt the data.[12] Since each transaction 
includes the digital signature, the parties to the transaction are known. Because it’s an 
encrypted key, the real-world identity of the parties can be protected. 
As you would expect, the ledger records transactions, like “Billy sends Sally 10 
Bitcoins”, but other pieces of data are required in the block as inputs to the hashing 
algorithm. Each transaction contains the digital signature of the sender and a timestamp. 
The hash value for the previous block is included as input for the current block. This 
inclusion forms the ‘chain’, with each new block being linked to the prior block. The 
input also includes a nonce, or “number used once”, which is a random numeric value 
that creates a hash that will be accepted by the blockchain. Other values are included 
as well, but these are the basic components of the input string. Once the inputs are 
assembled, the input string is hashed to create a 256-byte value. If the resulting value 
                                                          
7 Scott, “Blockchain” SMU MSDS term paper. 
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is accepted by the network, the block is added to the chain and validated by other 
members. The block is added to all the distributed nodes, and the process continues for 
the next block.  
In a proof-of-work implementation like Bitcoin, miners supply computing resources 
and receive compensation for adding valid blocks to the chain as well as transaction 
fees for each transaction in the block. Miners race to find a nonce value that will create 
an acceptable hash value from the data inputs. The network sets an adjustable threshold 
to regulate the difficulty and thus the length of time, for solving the puzzle of 
discovering a nonce to complete the block. This mechanism keeps a pace of one new 
block added to the chain every 10 minutes. As new blocks are added, they are 
considered ‘confirmation’ for the prior blocks. Once six confirmations have been added 
on top of a block, the data is considered immutable. At that stage, it’s not feasible with 
today’s computers to alter the input data for a block, find a new nonce, add a block with 
altered information, and then somehow race ahead to beat all the other computing 
resources on the network to rebuild an alternate chain.  
While this is a greatly simplified description, it provides a basic framework for 
understanding the blockchain technology. Since its introduction, Bitcoin blockchain 
has expanded functionality and now allows more types of transactions to be 
programmed into the blockchain. After ten years of effective use with Bitcoin, 
blockchain technology is now being considered as an alternative to centralized 
accounting ledgers and other track-and-trace record keeping systems. Plus, since it’s 
the forerunner of all other blockchain solutions, it’s important to understand the 
characteristic strengths and weaknesses of the technology. 
4.1   Key Characteristics of Bitcoin Blockchain 
Let’s take a closer look at the traits that, collectively, position the Bitcoin blockchain 
to provide a unique and compelling solution to the marketplace. 
Data Structure. Transactions are formatted into blocks that are linked together 
using a cryptographic hashing algorithm that takes as input data from prior entries such 
that the output is a secure chain of data in which one block cannot be altered without 
invalidating the hash. 
Distributed. Every node in the network contains a full copy of the dataset. 
Decentralized. An algorithm is used by the nodes to validate new entries, with 
entries that are validated by a majority of nodes included in the blockchain. Not only 
are transactions verified by consensus, but updates to the blockchain software are also 
accepted by consensus. 
Transparency with Privacy. Users have a digital signature, and each transaction 
includes the digital signature of the parties involved, but the signature is not easily 
associated with an individual or organization. 
Timestamps. Timestamping assures the order of transactions is accurate. 
Combining these traits creates a secure, publicly-sharable database that reliably records 
the time, content, and parties of each transaction without centralized control for data or 
software updates. Compare that to privately-held, centrally managed databases that are 
susceptible to alteration of individual data components. To simplify, traditional 
technology says “I have my data. You have your data. We have to validate and reconcile 
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activity between our databases using a bank or a trusted third party to facilitate.  As 
soon as the reconciliation concludes, either of us can change our data such that I no 
longer trust who you are or your data.” Blockchain technology has the potential to say 
“I know who you are. I know who owns this asset. We have a shared record of trusted, 
validated transactions; no reconciliation required.”  
As a result of these traits, blockchain offers several key benefits compared to 
traditional approaches. 
Data Integrity. The cryptographic, secure nature of the data structure removes 
questions about asset identity, asset ownership, and transaction history. Hashed blocks 
make it unfeasible to reverse or tamper with transactions. 
Operational Resilience. Distributed data model means data is always accurate and 
accessible. 
Built-in Audit Trail. Time and parties to transactions are built into the data structure 
itself, automatically establishing audit trails while protecting privacy since parties are 
identified only by public/private keys. 
Ownership. Provides an immutable record of ownership and effectively prevents 
double-spending of assets. 
The potential to create a secure, shared, immutable record of transactions and asset 
ownership is predicted to drive the mass adoption of blockchain technologies as the 
next logical step in application evolution. Blockchain instantiates trust as part of the 
application.  
4.2   Challenges of Bitcoin Blockchain  
While the promise of blockchain is great, the associated barriers and risks are also great. 
Some of the commonly sited challenges to the adoption of blockchain are listed below. 
Blockchain Applications not Impervious. The blockchain is a data store. As with 
any other data store, an application is written to leverage the functionality provided by 
the data store. Even if the data store is secure, the application may provide 
vulnerabilities. Exchanges have been hacked on multiple occasions since they store 
both public keys and private keys. Hackers can quickly drain wallets if they are able to 
break in and obtain the keys.  The underlying assumptions of the benefits of 
blockchain have been challenged by two well-publicized events. First, a cyber attack 
on Ethereum, a smart contracts blockchain application, improperly diverted $50M 
worth of tokens. To counter this attack, 85% of Ethereum users voted for a ‘hard fork’ 
of the chain, which essentially rolled back the effects of the attack and restarted the 
chain before the attack. The remaining 15% of users continued to use the affected data, 
referring to it as ‘Ethereum Classic’. The second event involved the bankruptcy of Mt. 
Gox, who held 70% of Bitcoin traffic in 2014. During the course of the bankruptcy, it 
was discovered that $450 million in Bitcoin was stolen from the bank.[13] These two 
events shook confidence in the blockchain software as vulnerabilities became apparent. 
Technical Limitations. Scalability is a critical concern as no cryptocurrency 
platform approaches processing the number of transactions with the speed of large 
payment systems like VISA.[14] Capacity, latency, and query capabilities are quite 
limited in comparison to other distributed database systems.[13] Currently, there are no 
protocols or standards for interoperability with blockchain. Even with the cryptographic 
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nature of blockchain, the breaches and vulnerabilities discussed earlier point toward 
remaining security challenges. Plus, with such a widely distributed architecture, there 
are simply more entry points for cyber-attacks to occur using methods unforeseen at 
this time. 
Government Regulation. Healthcare and pharmaceutics are heavily regulated, so 
any change in technology would need to be proven to comply with regulations. There 
has been no uniform regulation of cryptocurrencies globally let alone addressing the 
implications of a blockchains recording transactions for non-monetary assets. Plus, 
regulation can create a culture that does not quickly adopt change. “Years of heavy 
regulation and a long-standing focus on compliance have co-opted the ability of the 
healthcare industry to implement novel data sharing approaches. We now face a critical 
need for such innovation. The primary challenge to adoption of blockchain technology 
in healthcare is that it is still a nascent technology”.[12] Looking specifically at the US 
stock market system, much of the infrastructure has developed ‘organically’ over 
decades to meet needs of users and regulators. Switching to a whole new architecture 
would be risky, so rapid change of the infrastructure is unlikely. 
Conflicting International Law. The General Data Protection Regulation (GDPR) 
prevents misuse of personal information collected in databases for citizens of the 
European Union. The law was passed April 2016 but goes into effect May 2018. One 
tenant of this law is that people have the right to ask for their personal information to 
be removed from databases once the need for the data is complete. This requirement is 
in conflict with the architecture of blockchain. Because blockchain data is immutable, 
by definition the data can’t be removed. However, SQL databases, data changes are 
actually logged over time, so the probability that personal data is actually 100% deleted 
is not likely. The most likely implementation is that data should not be viewable, usable, 
or sharable. This could be accomplished by not putting personal data into the 
blockchain. Personal data could be kept in a different data store with a link to the 
external data being in the hashed blockchain. Given that decentralized blockchain 
applications have no way to remove prior data and no centralized authority to request 
removal from, it is essentially the responsibility of the person conducting transactions 
and putting data into the chain not to share personal information or not use the service. 
Other laws in the EU regulate where data can be stored, with some data not allowed 
outside country borders. Because the blockchain is usually replicated to all nodes, any 
global blockchain implementation is going to contain data from all participating 
countries in all nodes. 
While there has been no coordinated global regulation for cryptocurrencies or 
blockchain, many countries have begun regulation of their own. Most of the regulation 
revolves around what type of asset class cryptocurrencies should be considered, 
whether or not exchanges are legal, and enforcement of money laundering and “know 
your customer” laws. In addition, there is no consensus on what type of asset class 
cryptocurrencies should be considered, even within individual countries. In the United 
States, the SEC considers cryptocurrencies as securities, the Commodity Futures 
Trading Commission considers them a commodity, while the IRS considers them as 
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property. 8 Below is a summary of various governments’ current views on exchanges 
and Bitcoin’s use as legal tender. 
 
Table 1.  April 2018 Cryptocurrency and Exchange Status by Country 
Government Exchanges Legal 
Tender 
Japan Legal, if registered with the Japanese 
Financial Services Agency. 
Yes 
USA Legal, depending on the state. Must be 
registered with the SEC. 
No 





Legal and need to register with the Financial 
Conduct Authority. 
No 
South Korea Legal, if registered with South Korea's 





Singapore Legal, may fall under regulatory purview of 
the Monetary Authority of Singapore. 
No 
India Legal. The Indian government has issued 
warnings but does not currently regulate 
exchanges. 
No 
Switzerland Legal, need to register with the Swiss 
Financial Market Supervisory Authority. 
Yes 
 
Technocrats. While blockchain may move a process away from central authorities 
of banks and government regulation, it may draw its users toward the power of a 
technical oligarchy. He who controls processing power may control the blockchain. 
Changes to the Bitcoin blockchain software occur via a passive process when holders 
representing more than 50% of the network’s mining power adopt or reject a change. 
Since consensus decisions are based on mining power, there is a potential for the most 
powerful miners to accept only the code changes advantageous to themselves, shoring 
up their power. Other situations involving coercion or collusion are also conceivable. 
Lessor miners could receive compensation (aka bribes) for accepting code changes of 
little importance to themselves. Software changes could be packaged to deceive those 
accepting them. Advantageous changes may go unnoticed. This decentralization of 
authority over blockchain might leave it vulnerable to sabotage. Theoretically, a 
saboteur could compromise the integrity of the blockchain data either by having a much 
faster supercomputer than anyone else or by adding enough CPU power to the network 
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to control a majority of the mining power and organize a so-called “51% attack”. Thus, 
there is concern that this concentrates too much power and decision making in the hands 
of technologists, like developers and system administrators. If the system is coded and 
managed by a select group of technologists, it could be modified to their advantage or 
to the disadvantage of others. 
4.3   Addressing limitation of Bitcoin Blockchain 
New products and implementation options offer alternatives to the Bitcoin blockchain 
implementation to mitigate the challenges listed above. While the term ‘blockchain’ 
and ‘the blockchain’ are frequently used to refer specifically to the Bitcoin blockchain, 
a host of alternative solutions and complementary products have been introduced. 
Increasingly, the terms ‘shared ledger’ and ‘distributed ledger technology’ (DLT) as 
well ‘blockchain’ are used to generically refer to blockchain solutions. To be a 
‘blockchain’, most of the core benefits of the original must be preserved. Obviously, it 
must provide a decentralized ledger that provides trusted (immutable) provenance, 
transfer, and tracking of asset ownership. A common theme of most, if not all 
implementations, is the use of public key infrastructure to secure the asset and hashing 
routines to link and protect data integrity. 
Alternative implementations feature changes to application scale, the “wallet” 
asset, and the access paradigm. Mining is one of the core aspects of the Bitcoin 
implementation and was developed to both prevent the fraudulent creation of blocks 
and to entice dedication of computing resources to the blockchain. Miners receive 
transaction fees and tokens for creating blocks on the chain. Mining is one of the more 
controversial aspects of the bitcoin implementation and is modified in or excluded from 
alternatives. The processing power required to mine is considered ‘proof of work’. 
While proof of work plays a key role in securing the immutable nature of the chain, it 
also represents a tremendous amount of wasted computing power. Alternate 
implementations have moved to different methods, such as ‘proof of stake’ to provide 
a similar functionality while conserving the processing power and thereby increasing 
scale and throughput. The Bitcoin blockchain is used to record transactions for a 
cryptocurrency, but the “wallet” asset can be any physical or digital asset, such as a 
property title, a birth certificate, patient medical records, or ownership of a serialized 
drug. Lastly, while the Bitcoin blockchain is a public ledger, a permissioned, private 
blockchain implementation may be better for building a pharmaceutical supply chain 
ledger. Also, Bitcoin blockchain is purely decentralized. As aspects of software 
maintenance are governed by consensus and there no central authority. If you lose your 
private key, you lose your bitcoin. There is no authority to which you can appeal but 
there is also no central authority to be intimidated by a government. Some of the 
alternate implementations, such as what we are proposing for the pharmaceutical supply 
chain, require a bit of centralization and control to achieve the goals of the 
implementation. Miners are not collecting fees to supply resources, so participants are 
likely to supply computing resources and/or pay membership fees to participate. 
In addition, there are technologies emerging that are complementary to blockchain 
that greatly enhance the impact of the technology. One of the key technologies is ‘smart 
contracts’, which is a key feature of Ethereum. Smart contracts are not traditional legal 
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contracts. They are blocks of code that ‘autonomously’ execute transactions on the 
blockchain if conditions in the code are met. The power and promise of blockchain for 
supply chain application tends to lie the combination of three technologies: 1) using 
sensors embedded with the product as part of the IoT to record provenance and track 
location as well as a host of environmental factors, 2) using smart contracts to execute 
transactions when agreed upon conditions are met and 3) using blockchain to create an 
immutable record of it all, including current ownership of the asset. In this scenario, it 
seems reasonable that technology could remove enough risk to reduce the need for 
intermediation. “Blockchain-enabled smart contracts bring more certainty and 
reliability to online transactions than has been available to e-commerce environments 
for the past twenty years.” [16]. Smart contracts can deliver significant benefits to the 
way that we manage supply chains and regulate variable payments.  
5   Blockchain and Supply Chain Industry  
A range of uses for blockchain have been proposed for the healthcare and 
pharmaceutical industries. In 2016 Aptea and Petrovskyb proposed using blockchain to 
track the supply chain for excipient pharmaceuticals.[17] As of 2018, a wide assortment 
of blockchain programs are underway. We will highlight a selection of the pilot 
program implementations mentioned in scholarly works concerning the use of 
blockchain in the supply chain, paying special attention to those applications that 
provide provenance and traceability of products since those functions are key to 
DSCSA compliance. We started by reviewing applications supporting an array of 
industries within the supply chain and then moved to those applications supporting the 
pharmaceutical supply chain. We then assessed blockchain applications expressing 
support for the DSCSA.  
Provenance. Provenance conducted a pilot project in Indonesia to enable 
traceability in the fishing industry.[18] By using mobile phones, blockchain 
technology, and smart tagging, Provenance tracked fish caught by fishermen. The pilot 
successfully tracked fish in Indonesia for the first six months of 2016. In July 2016, 
Provenance started to work with the UK’s retailer Co-op in order to track fresh food 
such as fish, eggs, and dairy through its supply chain. Co-op customers are able to 
access information on the product journey through an app on their smartphones. 
Through deploying blockchain technology while collaborating with external certifiers 
and auditors, Provenance meets the increasing interest of customers to have reliable 
information about the source, safety, and sustainability of their products. 
Everledger. Working in partnership with Barclays, London-based startup 
Everledger offers a blockchain-enabled traceability application providing a fraud 
detection system for luxury items such as diamonds, art, and wine. The verification of 
the asset is recorded on the blockchain, and insurance companies, owners, and law 
enforcement can easily check if an asset has been registered. The main goal is to offer 
digital certificates to prevent insurance fraud as it’s estimated that almost 70% of 
fraudulent insurance claims are undetected. However, similar to Provenance, the ledger 
also offers reassurance about product source, in this case, that diamonds are ethically-
sourced from “conflict free” regions amid concerns rebel movements use diamonds to 
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finance wars against legitimate governments.[20] Everledger’s diamond registration 
application runs on a private Ethereum blockchain, provided by Eris Industries. [18,19] 
While Everledger’s diamond industry applications use a certificate system to 
authenticate diamonds, for wine Everledger attaches a tamper-evident RFID tag on the 
bottle’s cork. Maureen Downey’s company Chai Consulting and Everledger developed 
the Chai Wine Vault9 to protect high-end wines. The IBM-based ledger gives each 
bottle a unique digital identifier, including over 90 pieces of descriptive data related to 
ownership and storage history. The digital data is updated with ownership changes and 
storage records and can be used to verify provenance by retailers, warehouses, and 
auction houses. [20]  
Maersk. The Danish shipping company Maersk has successfully tested the use of 
blockchain applications in international logistics. They started by studying logistics 
requirements. In 2014, Maersk tracked a shipment of perishable goods from East Africa 
to Europe and discovered the shipment required stamps and approvals from up to 30 
people, including over 200 different interactions and communications. Afterward, 
Maersk partnered with IBM to start working on a version of its blockchain application 
based on the Linux Foundation's open source Hyperledger Fabric. IBM and Maersk 
conducted a successful proof of concept from September 2016 through February 2017, 
tracking three transcontinental shipments of perishable goods. A successful pilot 
project was completed in February 2017 that tracked an empty container from a 
customer site in France through its global transportation to the container’s destination 
in the US.[20] The project is expected to go into production by the end of 2017.10 
Walmart. On May 31, 2017, Walmart released the results of the food safety and 
traceability protocols test that started in October 2016. The first project involved 
tracking produce from Latin America to the United States. The second involved moving 
pork products from Chinese farms to Chinese stores. Walmart partnered with IBM to 
develop the service. Walmart reported that blockchain helped to reduce the time to track 
food from days to minutes.[20] 
Bext360. Denver-based startup Bext360’s app and cloud-based software employ 
Stellar blockchain to record timestamps and value of transactions on a real-time basis. 
It creates records of the origination of coffee beans as well as the price paid for the 
beans. Bext360’s first venture will be a kiosk, where farmers can sell beans. A mobile 
robot allows coffee buyers to assess the quality and weight of a farmer's product in the 
field while a mobile app supports the negotiation of a fair price. The farmers are paid 
in real-time via a mobile app.[20]  
Intel. In April 2017, Intel revealed a public demonstration that explains how a 
seafood supply chain can be tracked using its open-source Sawtooth Lake codebase.11. 
Data for four transactions from October 2016 was made public. The data included the 
record where a fisherman registered the fish upon catch and then sold it to a fishmonger, 
IoT telemetry and temperature data associated with the journey from the ocean to the 
fishmonger’s store, the fishmonger's record of selling to a seafood restaurant, and IoT 
telemetry and temperature data associated with the journey from the fishmonger to the 
seafood restaurant.[20] 
                                                          
9 Winefraud.com. https://www.winefraud.com/chai-wine-vault/. 
10 cointelegraph.com, 2017 
11 https://01.org/sawtooth/ 
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Clearly, these efforts demonstrate emerging capabilities achieved through the 
application of blockchain technology, especially when coupled with IoT and smart 
contract capabilities. Most of these trials are expecting to move beyond initial 
experimentation. However, as encouraging as these successful trials are, none are 
operating at a scale expected of a global enterprise application.  
 
5.1   Blockchain and Pharmaceutical Supply Chain 
We will now consider some proposals, trails, and implementations that are within the 
pharmaceutical supply chain. Shireesh Aptea and Nikolai Petrovskyb proposed the use 
of blockchain technology to establish provenance and track the excipient supply chain. 
Recall that excipients are components of drugs that are not the active ingredient. 
Tracking excipients is not part of DSCSA and there is far less risk of theft, diversion, 
or counterfeiting of them. But even so, much like people what to know where their fish 
comes from, using blockchain to track these components assures the safety and quality 
of the entire pharmaceutical supply chain. Of interest in the article was the insight that 
blockchain does not alleviate the need for a physical quality audit as data collected from 
sensors embedded in a shipment cannot fully guarantee the contents were not stolen, 
altered, or replaced with counterfeit goods [18]. 
Nuco. The blockchain company Nuco attempts to address three common tactics used 
in prescription drug fraud: modifying quantities to change the prescription itself, 
duplication of prescriptions and visits to many doctors to collect multiple original 
prescriptions. When a prescription is produced by a doctor, a machine-readable code is 
attached that serves as a unique identifier. This unique identifier is then associated with 
the name of the drug, the quantity, the patient, and a timestamp and then recorded on 
the blockchain. When the prescription is filled by a pharmacist, the symbol is scanned, 
the attempt to fulfill the prescription is compared against the blockchain, and the 
pharmacist is quickly informed whether the prescription is eligible to be filled. 
HealthChainRx and Scalamed are also working on blockchain solutions to combat 
prescription fraud. Several other healthcare-related blockchain applications are in 
initial stages, including Medicalchain, Healthcoin, BurstIQ, Factom, GemOS, 
HealthCombix, MedRec, Patientory, SimplyVital, and Bowhead. While these 
applications were related more to the patient experience or medical records than to 
supply chain, it’s telling to have so many projects initiated addressing different aspects 
of the healthcare experience [21].  
Modum. A recent regulatory change in the EU, known as Good Distribution Practice 
of Medicinal Products for Human Use12 requires companies to report any deviations in 
temperature or other conditions to the distributor as well as the recipient of the affected 
medicinal products. As a result, pharmaceutical drugs are being transported using 
expensive refrigerated trucks to maintain conditions that avoided notification, even if 
the drug did not need refrigeration to maintain potency [21]. Modum.io AG, a Swiss 
start-up, partnered with the University of Zurich to design a system to ensure the safe 
transportation of pharmaceutical drugs without the unnecessary use of refrigerated 
trucks by focusing on the products that can be stored at ambient temperatures (15°–
25 °C). Modum built a prototype and completed a first pilot project together with 
                                                          
12 GDP 2013/C 343/01 
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pharmaceutical distributors. From July 7th to August 12th 2016, a pilot project was 
conducted and medical goods were shipped weekly from one supplier to a 
pharmaceutical wholesaler. A Modem sensor monitors the temperatures of the 
medicines during transport and the data is transferred to the Ethereum blockchain after 
the trip. A Solidity-based smart contract compares the data against regulatory 
requirements, and if all the required conditions are fulfilled, the product is released. 
These results are publicly accessible and reported back to the receiver as well as to the 
distributor. Currently, modum.io AG is planning for a second pilot project with over 
500 shipments with more distributors and wholesalers. Must like DSCSA, the Falsified 
Medicines Directive (FMD)13 requires individual pharmaceutical packages to have a 
serial number to support tracking of medications at ‘per use’ level by 2019. Once 
packages are serialized, results may also be available to end customers [21].  
Gemalto. Gemalto has teamed up with an insurance company that covers the 
delivery of temperature-sensitive medicines from drug manufacturer to hospitals 
located in hot climates. Digital thermometers are used to record the temperature of 
drugs regularly and the data is added to a blockchain ledger. Blockchain helps to govern 
that process and provide assurance that safety requirements are met [21]. 
Blockverify. Blockverify is a US company trying to introduce Blockchain into the 
global pharmaceutical supply chain to avoid counterfeit and forgeries. [20] Their main 
business areas include pharmaceuticals, luxury items, diamonds, and electronics. 
Blockverify conducted a pilot project in the pharmaceutical sector using the Bitcoin 
blockchain together with a private side chain. Every product has its private key stored 
in the public blockchain that can be verified by anyone. With a track and trace number, 
it is possible to trace change of ownership, thus every change will be recorded in the 
private blockchain [21]. 
5.2   Blockchain application targeting DSCSA compliance 
Chronicled, a San Francisco-based blockchain startup, in conjunction with LinkLab, a 
life sciences supply chain consultancy, launched Mediledger, a blockchain-based 
compliance protocol to satisfy DSCSA.[20]   Like others, Chronicled is not limited 
to pharmaceuticals and is expanding their service to luxury items. Their blockchain is 
an open registry where information about buyers and sellers are stored. Luxury items 
are tagged for identification which allows everyone to check the history of buyers and 
sellers [21]. 
Mediledger provides provenance and traceability of drug shipments, supply chain 
integrity, and real-time global supply feedback using IoT. MediLedger’s stated purpose 
is to demonstrate compliance with the DSCSA and to create an operable system in 
which multiple parties can verify and transfer pharmaceutical products with absolute 
trust in their authenticity, based on blockchain technology. In March 2018, MediLedger 
released a year-end report in which they stated, “First, the Project's blockchain-based 
system appears to fully meet the requirements set forth by DSCSA and is capable of 
acting as the interoperable system for the pharmaceutical supply chain prescribed in the 
Act. In addition, MediLedger has proven that it can meet the data privacy requirements 
                                                          
13 EU 2016/161 
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of the pharmaceutical industry itself. In particular, it can guarantee that all supply chain 
handshake transactions posted to the blockchain are fully obfuscated, ensuring that no 
business intelligence is leaked. This will allow nodes in the blockchain system to be 
hosted by numerous unique parties while both safeguarding sensitive transactions and 
ensuring the immutability of each supply chain handshake transaction.”  
5.3 Encouraging Participation 
So far, the literature has assumed that pharmaceutical companies will comply with the 
law, regardless of the cost, because of the governance power of the FDA. However, can 
the FDA afford to punish all drug manufacturers and other supply chain participants if 
there is a widespread inability or unwillingness to comply? Perhaps more “carrot” and 
less “stick” will help encourage participation. Below are some ideas to incent 
pharmaceutical companies to collaborate in the building of a shared ledger. 
Expedite the approval process. This would reduce time to market for new drugs 
and give manufacturers quicker access to revenue that would help cover R & D costs. 
To protect consumers the FDA shouldn’t cut corners, they should devote more 
resources to the approval process of a drug that a manufacturer will agree to put on a 
distributed ledger. 
Grant patent extensions. This will allow the manufacturers to sell drugs they 
develop at a premium for longer before generics can legally be sold that eat into their 
market share. It can be argued that this would hurt consumers since they would have to 
pay a premium for longer, but manufacturers could reduce price and maintain the same 
profitability since their volume sold would increase. 
Mask the public keys associated with each distributed ledger participant.  
Keep all metadata encrypted inside of the blocks so that competitors can’t analyze the 
supply chain to gain competitive information. Auditors and regulatory bodies can be 
granted access to decrypt the information inside of a block in case of an audit or 
inspection [22]. 
6   Ethical Considerations 
6.1   Traceability of Pharmaceuticals 
Advertisers use labels like “organic”, “wild caught”, “sustainable sources”, “100% 
Colombian” to entice consumers to their premium brands. The reality is most of those 
claims can’t be substantiated. In fact, without DNA testing it’s difficult to tell if the 
white tuna ordered in a sushi restaurant truly is tuna or a cheaper substitute. Some of 
the blockchain projects above will prove if consumers are willing to buy brands with 
proven provenance and a traceable supply chain. Traceability of food sources will 
provide consumers with more choices. Traceability of luxury items may save insurance 
companies from fraud. Traceability of diamonds could reduce funds flowing to rebels 
in conflict zones who use them to finance their violence. In cases where there are human 
rights violations involved in the production of goods, the technology has the potential 
18
SMU Data Science Review, Vol. 1 [2018], No. 2, Art. 4
https://scholar.smu.edu/datasciencereview/vol1/iss2/4
  
to stop unethical and illegal practices, including slavery [20]. Traceability of 
pharmaceuticals is a matter of life or death. Counterfeit drugs cost lives around the 
world. In the US, we had the Heparin incident described above, but globally thousands 
of lives are lost when Malaria drugs are replaced with counterfeit drugs. As traceability 
is rapidly becoming a capability, ethically, we are bound to use these techniques to 
prevent criminals from tainting the prescription drug supply. While complying with the 
DSCSA will be difficult and expensive, it’s also an ethically compelling concept, 
especially if it can be implemented globally. 
6.2   Data Privacy 
Perhaps the greatest ethical challenge facing data science today is the dual-edge sword 
of data privacy. When to keep data hidden and when to reveal or use data is not only a 
sensitive topic, it’s one for which there are complex and changing global laws and 
growing consumer sensitivity. While patients may be willing to risk releasing their data 
into collections of population health data for the promise of longer and healthier lives, 
they may not want to release the same information for market research and the promise 
of more targeted advertising campaigns. It’s an area where opinions on ethical behavior 
differ widely, leaving lots of ‘gray’ territory. Having the local pharmacy publish your 
prescription drug purchases in the Sunday Times is not ethical. Pharmacies legally sell 
data concerning prescription drug purchases, anonymized to a zip code, for market 
research. People with a rare disorder may feel the zip code is not anonymized 
adequately while others purchasing a widely-prescribed drug may not care. Having the 
analytic power to identify when $40 million of opioids are shipped into a small market 
and holding those drug manufacturers accountable for the resulting explosion of opioid 
abuse would probably be considered an ethical application by most data science 
professionals14. Thus, our concept of ‘ethical’ treatment of data is based on how the 
data is used and data scientists must be informed not only about the laws but also about 
how the findings of any specific research effort might be used, even if the stated purpose 
seems noble. 
DSCSA. DSCSA is not causing additional data to be collected or distributed for 
individuals. In fact, the dispensing of the drug pursuant to a prescription is explicitly 
excluded from the law. Thus, DSCSA does not represent incremental data privacy 
issues for individuals. What is at risk are the trade secrets and privacy of each 
participating business entity. Industrial espionage is real and exposing transactional 
patterns to the marketplace could be a threat to the participants’ business. Thus, 
whatever data store is used must protect the participating entities from gaining unfair 
knowledge of inventory or trade practices of others in the supply chain. Since the point 
of DSCSA is to create transparency, this business need may be counter to enforcement 
of the Act. In this regard, blockchain offers some advantages because of the encryption. 
A blockchain does not easily lend itself to that type of analysis. The main requirement 
is to tightly control who would have access to the cryptographic keys as that capability 
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would unlock more ability to analyze the transaction data for patterns outside the stated 
purpose. 
Blockchain. Likewise, the use of blockchain to meet the requirements of DSCSA 
does not present new data privacy dilemmas specifically relative to prescription drugs 
as the ethical dilemmas are common to all types of data that can be traced to individuals 
or communities. With that said, blockchain does present two unique data privacy 
dilemmas by nature of the technology.  
First, blockchain data is ‘immutable’, it never goes away. Unlike an RDMS or any 
other data store, the data can’t simply be over-written with corrected information or 
‘blanked out’. The data has to be updated with information in a new block and all 
subsequent reporting would need to read the entire blockchain or risk using incorrect 
data. The GDPR, which requires that EU citizens be able to request their personal 
information be removed from any data store, has implications for blockchain since it’s 
not possible to delete data. This is one reason why a lot of implementations don’t use 
blockchain alone. The blockchain is used to record the transactional information that 
should not change, but personally identifiable information that could change is 
normally stored in a more traditional data store with the link to that data encoded in the 
blockchain. In fact, since data in a blockchain is hashed, it can only be accessed and 
read by people who have the appropriate software to do so, which is why it’s viewed 
as a more secure data store. As many investors in Bitcoin have discovered, if you lose 
your private cryptographic key, your bitcoin is unrecoverable. Going deeper, what if 
the original ownership entry being reported by the blockchain is incorrect? What if the 
person populating the blockchain with property deeds simply replaces their name as the 
rightful owner? What if medical records recorded in blockchain record an incorrect 
diagnosis or treatment that was not provided to that patient? HealthCombix, in 
collaboration with PointNurse, is attempting to address this by introducing a service 
provided by nurses to ensure that the data entered into the immutable blockchain record 
is accurate and that the patient understands how to access, update, and grant access to 
their records [23]. More so than other data stores, the potential impact of incorrect data 
being instantiated into the blockchain must be considered by the designers with 
contingencies to address that occurrence built into the application if the data coming 
into the application could be wrong. 
Second, because the data is encoded and parties to a transaction are obscured by the 
use of cryptographic keys, blockchain can be used to protect the identities of parties 
involved in criminal activities. Since a public blockchain has no centralized authority, 
there is no organization to serve a warrant to force disclosure of activity or identities. 
This has been an ongoing criticism of bitcoin and why it is so closely associated with 
the Dark Web. Decentralization is also why citizens in countries with corrupt banking 
systems are willing to trust Bitcoin instead of their state-governed bank. As with most 
technology, the ethical dilemma lies with the use case, not the technology. 
7   Conclusion 
When considering the viability of blockchain-based applications, most sources agree 
that the technology’s biggest barrier is simply that it’s too new. Regulations have not 
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been created. Technical understanding of the technology is limited and has not yet 
spread. Successful pilots have not been turned into successful applications at scale. 
However, last year, this same research group conducted a survey of literature for 
blockchain. At that time, there were a plethora of scholarly articles explaining 
blockchain and proposing applications for the new technology beyond cryptocurrency, 
mostly in the financial sector. This year, the articles have shifted to presentations and 
evaluations of pilot programs, with many articles presenting case studies on several 
different use cases relevant to supply chain. We discovered a wide array of pilot 
programs, including programs backed by significant industry leaders and global 
enterprise organizations like IBM, Wal-Mart, and Maersk, in addition to the expected 
array of start-up efforts. Most articles still predicted growth for the adoption of 
blockchain, even if they disputed the hype that blockchain would be an industry 
disruptor. We have demonstrated that blockchain, in theory, offers unique benefits to 
meet requirements for supply chain traceability. Yet, the technology is still unproven 
at the scale and performance that will be required to integrate into supply chain 
applications. While MediLedger’s year-end statement is promising, their industry 
claims must be substantiated. 
Certainly, the social climate supports traceability, if not the technology to achieve it. 
Consumers want more information about the provenance and traceability of foods so 
they will be more informed about quality and sustainability. How much more so would 
patients want assurances that their medications are safe and effective? With so much 
value in the pharmaceutical supply chain and the risk of death a real possibility, the cost 
justification is not difficult if traceability can prevent counterfeit or compromised drugs 
from reaching patients.  
On the other hand, while blockchain offers promise, the current state of the supply 
chain industry may make adopting blockchain difficult. Blockchain is a data store. 
When coupled with IoT technology and smart contracts, it creates a compelling vision 
for a new paradigm, but what blockchain lacks is the thing supply chain needs the most 
to support automation: standardized data models. The supply chain industry is simply 
not prepared to adopt a shared ledger technology until/unless there is more 
commonality in how participants exchange data [24]. With that in mind, Modum may 
have the right approach. Instead of starting off with a full-fledged solution for drug 
traceability, solve smaller problems, gain experience, and build to a wider solution. 
Maersk seems to be taking the same “start small, gain experience” approach to their 
implementation. Focusing on the requirements for DSCSA, in essence, carves out a 
subset of the overall pharmaceutical supply chain functionality and allows focus on a 
portion of the problem with a stated data model.  
2018 will be a pivotal year for blockchain adoption. As pilot programs end, 
organizations will decide if they are going to continue investing in the technology. 
Apparently, several key players recently confirmed that position. Forbes reported on a 
recent panel discussion about blockchain adoption from the technology community. 
Speakers included Anant Kadiyala, Director of Blockchain & Industry Solutions at 
Oracle; IBM's David Noller, Executive Architect Watson IoT - Blockchain and 
Industry 4.0; and Steven Kim, a Senior Director at SAP. The user community was 
represented by Jeff Denton, the Senior Director of Global Secure Supply Chain at 
AmerisourceBergen, one of the largest pharmaceutical distributors in the world. For a 
wide variety of use cases, Mr. Denton believes you start by assuming blockchain will 
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be the answer and only explore other technologies if you can prove blockchain doesn't 
work. According to Mr. Kim of SAP, "2018 will be a milestone year that we will see 
the adoption of a first set of blockchain solutions in enterprise applications - from 
securing the pharmaceutical supply chain to eliminating inefficiency in international 
logistics." Both Mr. Noller of IBM and Mr. Kadiyala of Oracle agree that 2018 will be 
the year that blockchain moves from pilots to everyday usage in business applications.15 
Since DSCSA compliance is not required until 2023, that provides time for the market 
to gain experience and knowledge while blockchain technology matures. 
8  Summary 
By 2023, DSCSA requires the consistent traceability of pharmaceutical products from 
manufacturer to dispenser within the United States. Participants in the supply chain are 
expected to verify the chain of ownership, detect suspicious activity, and respond 
accordingly as outlined by the law. In addition, participants must be able to quickly 
respond to requests for information from enforcement officials. The final outcome of 
Title II will be the creation of an electronic, interoperable traceability system for 
pharmaceutical products at the package-level. The goal is to use real-time data capture 
to detect, respond to, and report potentially illegitimate drugs faster and more 
effectively before they can become a safety hazard to patients. The DSCSA was created 
to curb the circulation and sale of illegitimate pharmaceutical products. However, 
achieving this goal requires creating a reliable system of record with appropriate 
visibility to identify legitimate pharmaceuticals for all participants in the supply chain. 
Since members in the supply chain have compelling business reasons not to share 
information on inventory, a key challenge to ensuring compliance with traceability 
requirements will be establishing trust among stakeholders. 
Blockchain applications are uniquely designed to provide traceability and to 
introduce trust into a trust-less system. As such, providing traceability of 
pharmaceuticals through the supply chain is a suitable use case for a blockchain 
implementation. This review demonstrated how a blockchain technology can provide 
functionality that benefits supply chain management in general and traceability of 
pharmaceuticals in particular. We identified several blockchain pilot programs relevant 
to traceability conducted by both global enterprises and start-up companies. However, 
none of these have the maturity to prove blockchain can operate at the scale required to 
support DSCSA compliance. Supply chain applications focused on compliance with 
track-and-track regulations like DSCSA may be the turning point for blockchain to 
prove it’s worthy of the hype as an industry disruptor. 
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This project originated as a proof of concept. Our efforts failed, but in the interest of 
disclosure, we wanted to list some resources and methods we tried in hopes that it will 
help others. Initial efforts focused on using the Interplanetary Database (IPDB) which 
was touted as an internet-scale blockchain database. However, according to a post on 
ipdb.io in January 2018, “The world has changed, and funding to maintain and operate 
IPDB while maintaining its core values became an insurmountable struggle.” 16  We 
speculate that funding may have dried up for IPDB due to the upcoming GDPR law. 
Since ipdb.io cited that BigChainDB17 had been instrumental in their test network 
development, a combination of BigChainDB and MongoDB running in a Linux 
environment was next explored. While some limited success was obtained by following 
online documentation, we did not find the BigChainDB implementation had the ease of 
use required for the timeframe we were seeking to build the POC. Although 
BigChainDB seems to be a promising commercial product to build blockchains, the 
support is too expensive for an academic exercise and the open source implementation 
proved to be difficult. 
After some searching for a simpler method, a Python tutorial was found on a 
blogpost at hackernoon.com that showed a straight forward method for building a 
blockchain. The code tutorial from the hackernoon article details how to build Rest 
APIs with Python libraries hashlib, json, and flask. The application operates using 
HTTP requests. The author of the tutorial suggests the use of cURL or Postman for 
testing the HTTP requests. Postman is cost prohibitive for testing due to the limited 
number of free transactions (1,000) while cURL did not interact well with Windows 
10. We discovered an open source application named Advanced Rest Client which we 
used to test transferring data between the blockchain application and the client. While 
the code to read and write data was relatively straightforward, communication between 
nodes was unattainable.  
Just after conclusion of our research, Amazon announced availability of their free 
blockchain templates. The authors recommend exploring those capabilities. 
                                                          
16 IPDB webpage. Retrieved from https://ipdb.io/ 
17 https://docs.bigchaindb.com/en/latest/ 
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